Qiagen N.V. (QGEN) 21.87 $QGEN
QIAGEN Announces Successful Completion of Tender Offer for Shares in Exiqon
PR Newswire - Thu Jun 23, 4:45AM CDT
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the successful completion of the conditional, voluntary public tender offer for the shares in Exiqon A/S, a world leader in RNA technology. The extended Offer Period expired yesterday, on 22 June 2016, at 23.59 (CET).
QGEN: 21.87 (+0.12)
After Yesterday's Rally of 1.31% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Jun 22, 1:58PM CDT
QIAGEN (NASDAQ:QGEN) traded in a range yesterday that spanned from a low of $21.26 to a high of $21.86. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $21.46 on volume of 1.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
QGEN: 21.87 (+0.12)
Qiagen's Q1 Results Hit by Currency, Competition Rife
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 8:32AM CDT
Qiagen (QGEN) is facing increasing competition from firms that provide pre-analytical solutions and other products.
BSX: 22.88 (+0.22), BAX: 45.27 (+0.33), LMAT: 14.82 (+0.13), QGEN: 21.87 (+0.12)
Active Equities to Watch in the Services Sector -- Booz Allen Hamilton Holding, Qiagen, INC Research Holdings, and Myriad Genetics
PR Newswire - Fri Jun 17, 7:20AM CDT
On Thursday, June 16, 2016, the NASDAQ Composite ended the trading session at 4,844.92, up 0.21%; the Dow Jones Industrial Average advanced 0.53% to finish at 17,733.10; and the S&P 500 closed at 2,077.99, up 0.31%. The gains were broad based as seven out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Booz Allen Hamilton Holding Corporation (NYSE: BAH), Qiagen N.V. (NASDAQ: QGEN), INC Research Holdings Inc. (NASDAQ: INCR), and Myriad Genetics Inc. (NASDAQ: MYGN). Learn more about these stocks by accessing their free trade alerts at:
MYGN: 31.03 (+0.06), BAH: 29.16 (+0.24), INCR: 38.69 (+0.25), QGEN: 21.87 (+0.12)
Qiagen???s QIAsure Test to Determine Cervical Cancer Risks
Zacks Equity Research - Zacks Investment Research - Wed Jun 15, 7:33AM CDT
Qiagen's (QGEN) QIAsure accurately stratifies cervical cancer risk, which offers highly sensitive and specific results for patients and clinicians.
BAX: 45.27 (+0.33), LMAT: 14.82 (+0.13), QGEN: 21.87 (+0.12), NUVA: 58.47 (+0.68)
QIAGEN Changes Offer Conditions for Acquisition of Shares in Exiqon A/S
PR Newswire - Wed Jun 08, 9:13AM CDT
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced its decision to change the offer conditions for the acquisition of shares in Exiqon A/S, reducing the threshold from 90% to 89.20%. All other terms and conditions remain unchanged. In line with the Danish Takeover Order, which requires the extension of an offer period in case of changing offer terms and conditions, QIAGEN N.V. is further extending the offer period, which will now expire on 22 June 2016 at 23:59 (CET).
QGEN: 21.87 (+0.12)
QIAGEN Announces Second Offer Extension for the Acquisition of Shares in Exiqon A/S
PR Newswire - Fri Jun 03, 8:30AM CDT
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced another extension of the Offer Period for the acquisition of Exiqon A/S, a world leader in RNA technology. On 18 April 2016, QIAGEN N.V. had published a conditional, voluntary public tender offer for the shares in Exiqon A/S, in which the shareholders were offered a cash amount of DKK 18 for each share held in Exiqon A/S. This Offer Period had been extended on 19 May 2016, its terms and conditions remained unchanged. In accordance with the Offer, the extended Offer Period expired yesterday on 2 June 2016 at 23.59 (CET).
QGEN: 21.87 (+0.12)
QIAGEN Forms Lung Cancer Expert Alliance
PR Newswire - Thu Jun 02, 3:05PM CDT
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the formation of a global consortium of international lung cancer experts who will advise the company on the design of new next-generation sequencing (NGS) gene panels and associated workflows that target lung cancer-specific mutations.
QGEN: 21.87 (+0.12)
QIAGEN Launches Liquid Biopsy Workflow for GeneReader NGS System
PR Newswire - Wed Jun 01, 3:05PM CDT
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of its liquid biopsy workflow for clinical cancer research using QIAGEN's GeneReader NGS System for next-generation sequencing (NGS). The Actionable Insights Tumor Panel, a member of the growing family of GeneRead QIAact Panels, is the industry's first complete Sample to Insight NGS solution for both non-invasive liquid biopsies and FFPE tissue samples. The panel is now optimized for NGS analysis of blood plasma using proven automated QIAGEN sample technologies for circulating cell-free DNA (cfDNA), enabling both tumor characterization and monitoring of cancer resistance markers as a complement to initial tissue biopsies.
QGEN: 21.87 (+0.12)
QIAGEN Integrates Quality Control Tools into GeneReader NGS System
PR Newswire - Tue May 31, 3:05PM CDT
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that an extensive package consisting of a quality control set and verification data will be offered with its GeneReader NGS System, reinforcing the proven accuracy of its next-generation sequencing (NGS) workflow and facilitating system setup, quality assurance and training for laboratories. QIAGEN has incorporated the Horizon Discovery Group's industry-standard reference control data set into the GeneReader NGS workflow to support clinical cancer research users from Sample to Insight.
QGEN: 21.87 (+0.12)
Qiagen, Therawis Diagnostics to Develop Breast Cancer Test
Zacks Equity Research - Zacks Investment Research - Fri May 27, 6:47AM CDT
With the global cancer diagnostic market expected to grow at a CAGR of 7.6% to $168.6 billion by 2020, we expect Qiagen (QGEN) to garner higher profits on account of this collaboration.
BSX: 22.88 (+0.22), SRDX: 23.52 (+0.17), BAX: 45.27 (+0.33), QGEN: 21.87 (+0.12)
QIAGEN Partners to Develop Predictive Tests in Oncology
PR Newswire - Wed May 25, 3:05PM CDT
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that the company has entered into a licensing and co-development agreement with Therawis Diagnostics GmbH to develop and commercialize predictive assays in oncology. An initial project will be to develop and market PITX2 as a marker to predict effectiveness of anthracycline treatment in triple negative and other high-risk breast cancer patients.
QGEN: 21.87 (+0.12)
QIAGEN Extends Tender Offer Period for Acquisition of Exiqon A/S
PR Newswire - Thu May 19, 9:30AM CDT
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the extension of the offer period for the acquisition of Exiqon A/S, a world leader in RNA technology. On 18 April 2016, QIAGEN had published a conditional, voluntary public tender offer for the shares in Exiqon, in which the shareholders of Exiqon were offered a cash amount of DKK 18 for each share they held in Exiqon. In accordance with the Offer, the Offer Period expired yesterday on 18 May 2016 at 23.59 (CET).
QGEN: 21.87 (+0.12)
Qiagen NV Looks for a Strong Second Half
Brian Orelli, The Motley Fool - Motley Fool - Tue May 03, 7:00PM CDT
Qiagen released first-quarter earnings on Thursday, with stagnant growth and investments cutting into the bottom line. The second half of the year looks to be more impressive, but let's take a look at the current quarter for now. Qiagen ...
ILMN: 142.49 (+1.60), QGEN: 21.87 (+0.12)
Qiagen (QGEN) Q1 Earnings Meet, Revenues Top; View Intact
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 12:26PM CDT
Qiagen (QGEN) started 2016 on a promising note with a satisfactory first quarter.
BSX: 22.88 (+0.22), QGEN: 21.87 (+0.12), NUVA: 58.47 (+0.68), OFIX: 44.60 (+0.27)
Qiagen meets 1Q profit forecasts
Automated Insights - Wed Apr 27, 3:49PM CDT
VENLO, Netherlands (AP) _ Qiagen NV (QGEN) on Wednesday reported first-quarter profit of $14.9 million.
QGEN: 21.87 (+0.12)
QIAGEN Reports Results for First Quarter of 2016
PR Newswire - Wed Apr 27, 3:13PM CDT
-- Adjusted net sales $298.4 million (+2% constant exchange rates, 0% actual); adjusted operating income $53.4 million; adjusted EPS $0.19 ($0.19 CER)
QGEN: 21.87 (+0.12)
QIAGEN Publishes Offer Document in Connection with the Conditional Voluntary Takeover Offer for the Shares in Exiqon A/S
PR Newswire - Tue Apr 19, 1:50AM CDT
QIAGEN N.V. ("NASDAQ: QGEN; Frankfurt Prime Standard: QIA"
announced on 29 March 2016 that QIAGEN N.V had decided to make a conditional, voluntary public tender offer for the shares of Exiqon A/S in which the shareholders of Exiqon are offered a cash amount of DKK 18 for each share they hold in Exiqon A/S (the "Offer".
QGEN: 21.87 (+0.12)
QIAGEN Launches Streamlined Bioinformatics for RNA Sequencing of Liquid Biopsies
PR Newswire - Thu Apr 14, 3:05PM CDT
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced introduction of its unique RNA-seq Explorer Solution, a bioinformatics-driven approach to analysis and interpretation of "omics" data from liquid biopsy-based research. RNA-seq Explorer Solution is a new tool which integrates Ingenuity® Pathway Analysis(TM), Biomedical Genomics Workbench® and other QIAGEN bioinformatics solutions to generate clear insights for research into improved detection, diagnosis and treatment of cancer. The solution will be demonstrated at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans.
QGEN: 21.87 (+0.12)
QIAGEN Posts 2015 Annual Report on Its Website
PR Newswire Europe - Wed Apr 13, 10:39AM CDT
VENLO, the Netherlands, April 13, 2016 /PRNewswire/ --
QGEN: 21.87 (+0.12)
QIAGEN Announces Successful Completion of Tender Offer for Shares in Exiqon
PR Newswire - Thu Jun 23, 4:45AM CDT
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the successful completion of the conditional, voluntary public tender offer for the shares in Exiqon A/S, a world leader in RNA technology. The extended Offer Period expired yesterday, on 22 June 2016, at 23.59 (CET).
QGEN: 21.87 (+0.12)
After Yesterday's Rally of 1.31% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Jun 22, 1:58PM CDT
QIAGEN (NASDAQ:QGEN) traded in a range yesterday that spanned from a low of $21.26 to a high of $21.86. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $21.46 on volume of 1.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
QGEN: 21.87 (+0.12)
Qiagen's Q1 Results Hit by Currency, Competition Rife
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 8:32AM CDT
Qiagen (QGEN) is facing increasing competition from firms that provide pre-analytical solutions and other products.
BSX: 22.88 (+0.22), BAX: 45.27 (+0.33), LMAT: 14.82 (+0.13), QGEN: 21.87 (+0.12)
Active Equities to Watch in the Services Sector -- Booz Allen Hamilton Holding, Qiagen, INC Research Holdings, and Myriad Genetics
PR Newswire - Fri Jun 17, 7:20AM CDT
On Thursday, June 16, 2016, the NASDAQ Composite ended the trading session at 4,844.92, up 0.21%; the Dow Jones Industrial Average advanced 0.53% to finish at 17,733.10; and the S&P 500 closed at 2,077.99, up 0.31%. The gains were broad based as seven out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Booz Allen Hamilton Holding Corporation (NYSE: BAH), Qiagen N.V. (NASDAQ: QGEN), INC Research Holdings Inc. (NASDAQ: INCR), and Myriad Genetics Inc. (NASDAQ: MYGN). Learn more about these stocks by accessing their free trade alerts at:
MYGN: 31.03 (+0.06), BAH: 29.16 (+0.24), INCR: 38.69 (+0.25), QGEN: 21.87 (+0.12)
Qiagen???s QIAsure Test to Determine Cervical Cancer Risks
Zacks Equity Research - Zacks Investment Research - Wed Jun 15, 7:33AM CDT
Qiagen's (QGEN) QIAsure accurately stratifies cervical cancer risk, which offers highly sensitive and specific results for patients and clinicians.
BAX: 45.27 (+0.33), LMAT: 14.82 (+0.13), QGEN: 21.87 (+0.12), NUVA: 58.47 (+0.68)
QIAGEN Changes Offer Conditions for Acquisition of Shares in Exiqon A/S
PR Newswire - Wed Jun 08, 9:13AM CDT
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced its decision to change the offer conditions for the acquisition of shares in Exiqon A/S, reducing the threshold from 90% to 89.20%. All other terms and conditions remain unchanged. In line with the Danish Takeover Order, which requires the extension of an offer period in case of changing offer terms and conditions, QIAGEN N.V. is further extending the offer period, which will now expire on 22 June 2016 at 23:59 (CET).
QGEN: 21.87 (+0.12)
QIAGEN Announces Second Offer Extension for the Acquisition of Shares in Exiqon A/S
PR Newswire - Fri Jun 03, 8:30AM CDT
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced another extension of the Offer Period for the acquisition of Exiqon A/S, a world leader in RNA technology. On 18 April 2016, QIAGEN N.V. had published a conditional, voluntary public tender offer for the shares in Exiqon A/S, in which the shareholders were offered a cash amount of DKK 18 for each share held in Exiqon A/S. This Offer Period had been extended on 19 May 2016, its terms and conditions remained unchanged. In accordance with the Offer, the extended Offer Period expired yesterday on 2 June 2016 at 23.59 (CET).
QGEN: 21.87 (+0.12)
QIAGEN Forms Lung Cancer Expert Alliance
PR Newswire - Thu Jun 02, 3:05PM CDT
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the formation of a global consortium of international lung cancer experts who will advise the company on the design of new next-generation sequencing (NGS) gene panels and associated workflows that target lung cancer-specific mutations.
QGEN: 21.87 (+0.12)
QIAGEN Launches Liquid Biopsy Workflow for GeneReader NGS System
PR Newswire - Wed Jun 01, 3:05PM CDT
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of its liquid biopsy workflow for clinical cancer research using QIAGEN's GeneReader NGS System for next-generation sequencing (NGS). The Actionable Insights Tumor Panel, a member of the growing family of GeneRead QIAact Panels, is the industry's first complete Sample to Insight NGS solution for both non-invasive liquid biopsies and FFPE tissue samples. The panel is now optimized for NGS analysis of blood plasma using proven automated QIAGEN sample technologies for circulating cell-free DNA (cfDNA), enabling both tumor characterization and monitoring of cancer resistance markers as a complement to initial tissue biopsies.
QGEN: 21.87 (+0.12)
QIAGEN Integrates Quality Control Tools into GeneReader NGS System
PR Newswire - Tue May 31, 3:05PM CDT
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that an extensive package consisting of a quality control set and verification data will be offered with its GeneReader NGS System, reinforcing the proven accuracy of its next-generation sequencing (NGS) workflow and facilitating system setup, quality assurance and training for laboratories. QIAGEN has incorporated the Horizon Discovery Group's industry-standard reference control data set into the GeneReader NGS workflow to support clinical cancer research users from Sample to Insight.
QGEN: 21.87 (+0.12)
Qiagen, Therawis Diagnostics to Develop Breast Cancer Test
Zacks Equity Research - Zacks Investment Research - Fri May 27, 6:47AM CDT
With the global cancer diagnostic market expected to grow at a CAGR of 7.6% to $168.6 billion by 2020, we expect Qiagen (QGEN) to garner higher profits on account of this collaboration.
BSX: 22.88 (+0.22), SRDX: 23.52 (+0.17), BAX: 45.27 (+0.33), QGEN: 21.87 (+0.12)
QIAGEN Partners to Develop Predictive Tests in Oncology
PR Newswire - Wed May 25, 3:05PM CDT
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that the company has entered into a licensing and co-development agreement with Therawis Diagnostics GmbH to develop and commercialize predictive assays in oncology. An initial project will be to develop and market PITX2 as a marker to predict effectiveness of anthracycline treatment in triple negative and other high-risk breast cancer patients.
QGEN: 21.87 (+0.12)
QIAGEN Extends Tender Offer Period for Acquisition of Exiqon A/S
PR Newswire - Thu May 19, 9:30AM CDT
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the extension of the offer period for the acquisition of Exiqon A/S, a world leader in RNA technology. On 18 April 2016, QIAGEN had published a conditional, voluntary public tender offer for the shares in Exiqon, in which the shareholders of Exiqon were offered a cash amount of DKK 18 for each share they held in Exiqon. In accordance with the Offer, the Offer Period expired yesterday on 18 May 2016 at 23.59 (CET).
QGEN: 21.87 (+0.12)
Qiagen NV Looks for a Strong Second Half
Brian Orelli, The Motley Fool - Motley Fool - Tue May 03, 7:00PM CDT
Qiagen released first-quarter earnings on Thursday, with stagnant growth and investments cutting into the bottom line. The second half of the year looks to be more impressive, but let's take a look at the current quarter for now. Qiagen ...
ILMN: 142.49 (+1.60), QGEN: 21.87 (+0.12)
Qiagen (QGEN) Q1 Earnings Meet, Revenues Top; View Intact
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 12:26PM CDT
Qiagen (QGEN) started 2016 on a promising note with a satisfactory first quarter.
BSX: 22.88 (+0.22), QGEN: 21.87 (+0.12), NUVA: 58.47 (+0.68), OFIX: 44.60 (+0.27)
Qiagen meets 1Q profit forecasts
Automated Insights - Wed Apr 27, 3:49PM CDT
VENLO, Netherlands (AP) _ Qiagen NV (QGEN) on Wednesday reported first-quarter profit of $14.9 million.
QGEN: 21.87 (+0.12)
QIAGEN Reports Results for First Quarter of 2016
PR Newswire - Wed Apr 27, 3:13PM CDT
-- Adjusted net sales $298.4 million (+2% constant exchange rates, 0% actual); adjusted operating income $53.4 million; adjusted EPS $0.19 ($0.19 CER)
QGEN: 21.87 (+0.12)
QIAGEN Publishes Offer Document in Connection with the Conditional Voluntary Takeover Offer for the Shares in Exiqon A/S
PR Newswire - Tue Apr 19, 1:50AM CDT
QIAGEN N.V. ("NASDAQ: QGEN; Frankfurt Prime Standard: QIA"
announced on 29 March 2016 that QIAGEN N.V had decided to make a conditional, voluntary public tender offer for the shares of Exiqon A/S in which the shareholders of Exiqon are offered a cash amount of DKK 18 for each share they hold in Exiqon A/S (the "Offer". QGEN: 21.87 (+0.12)
QIAGEN Launches Streamlined Bioinformatics for RNA Sequencing of Liquid Biopsies
PR Newswire - Thu Apr 14, 3:05PM CDT
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced introduction of its unique RNA-seq Explorer Solution, a bioinformatics-driven approach to analysis and interpretation of "omics" data from liquid biopsy-based research. RNA-seq Explorer Solution is a new tool which integrates Ingenuity® Pathway Analysis(TM), Biomedical Genomics Workbench® and other QIAGEN bioinformatics solutions to generate clear insights for research into improved detection, diagnosis and treatment of cancer. The solution will be demonstrated at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans.
QGEN: 21.87 (+0.12)
QIAGEN Posts 2015 Annual Report on Its Website
PR Newswire Europe - Wed Apr 13, 10:39AM CDT
VENLO, the Netherlands, April 13, 2016 /PRNewswire/ --
QGEN: 21.87 (+0.12)
